Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

FDA Approved. | Image Credit: wladimir1804 - stock.adobe.com
FDA Approves Denosumab Biosimilars Stoboclo and Osenvelt

March 4th 2025

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations.

FDA Approved. | Image Credit: Nirusmee - stock.adobe.com
First Insulin Aspart Biosimilar Receives FDA Approval

February 20th 2025

Osteoporosis. | Image Credit: Nisit - stock.adobe.com
Denosumab Biosimilars Approved With Interchangeability to Address Osteoporosis, Fracture Risk

February 18th 2025

Insulin. | Image Credit: Sherry Young- stock.adobe.com
Biosimilar Insulin Linked to Lower Prices in Europe

February 12th 2025

FDA approved. | Image Credit: Olivier Le Moal - stock.adobe.com
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra

January 31st 2025

Continuing Medical Education
View All
April 30th 2025

New and Approved: FDA’s 2024 Drug Lineup

1.5 Credits / General Pharmacy
April 30th 2025

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

More News

identical vials in a row
February 26th 2023

Gastroenterologists, Rheumatologists Cite Greatest Familiarity With Biosimilars

Laura Joszt, MA
A Cardinal Health report reviewed the potential impact biosimilars will have in rheumatology, gastroenterology, dermatology, and ophthalmology.
PA Is Part of an “Antiquated System” With Patient Safety, Workforce Burnout Implications
February 21st 2023

PA Is Part of an “Antiquated System” With Patient Safety, Workforce Burnout Implications

Laura Joszt, MA
close up of a closed eye
February 20th 2023

Retinal Physicians Report Reservations Around Ophthalmology Biosimilars

Laura Joszt, MA
There are 2 ranibizumab biosimilars approved in the United States, and with more ranibizumab and the first aflibercept biosimilars on the horizon, gaps in knowledge among retinal physicians should be addressed.
rendering of a molecule
February 16th 2023

The Growing Wave of Biosimilars for Autoimmune Diseases

Laura Joszt, MA
When the first adalimumab (Humira) biosimilar launched at the end of January, it was just the beginnings of a wave of coming biosimilars for anti-inflammatory biologics.
Site Logo
February 8th 2023

Humira: The First $20 Billion Drug

Jason B. Gibbons, PhD Micaela Laber, MPH, MBA Charles L. Bennett, MD, PhD, MPP
The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.
rows of identical vials
January 31st 2023

First Humira Biosimilar, Amjevita, Launches in the United States

Laura Joszt, MA
The first of at least 8 adalimumab biosimilars has finally launched in the United States after being kept off the market for years due to settlement agreements with the maker of the reference product, Humira.
stethoscope on top of money
January 27th 2023

Drug Prices to Continue Upward Trend Even as Biosimilars Enter the Market

Laura Joszt, MA
Multiple adalimumab biosimilars will hit the US market in 2023, but the drug is still projected to have the largest price increase for the calendar year starting July 1.
intravenous drip
January 21st 2023

Sintilimab Plus Bevacizumab Biosimilar Improves Response Rates, Depth of Response in HCC

Laura Joszt, MA
Compared with sorafenib, a combination of sintilimab and a bevacizumab biosimilar improved responses in patients with unresectable hepatocellular carcinoma (HCC).
Ken Cohen interview
January 18th 2023

Dr Ken Cohen Discusses the Role of Prior Authorizations in Value-Based Care

Laura Joszt, MA Justina Petrullo
Ken Cohen, MD, director of translational research for Optum Care, talks about the value of prior authorizations in different contexts, and how simplicity can benefit the process in some situations.
Cost of biologics
January 17th 2023

Biosimilar Competition to Herceptin Helped Reduce Price of All Forms of Trastuzumab

Allison Inserro
close up of a closed eye
January 14th 2023

With 2 Biosimilars Available, Use Remains Low Among Ophthalmologists

Laura Joszt, MA
Two ranibizumab biosimilars launched in the United States in 2022, but a new report shows comfort and familiarity with biosimilars has gone down compared with a year ago.
Screenshot of Ken Cohen, MD, from a video interview
January 6th 2023

Dr Ken Cohen Speaks on the Impact of Market Power on Biosimilar Uptake

Justina Petrullo Laura Joszt, MA
Ken Cohen, MD, director of translational research for Optum Care, speaks on the future of more biosimilars hitting the market, and how they will influence value-based care.
close up of money
January 1st 2023

PBMs Announce 2023 Coverage Plans for Adalimumab Biosimilars

Laura Joszt, MA
The addition of adalimumab biosimilars to formularies can help accelerate realized savings as the blockbuster drug Humira faces competition from multiple biosimilars, including 1 approved interchangeable biosimilar.
Top 5 Most-Read AJMC® Journal Articles of 2022
December 25th 2022

Top 5 Most-Read AJMC® Journal Articles of 2022

Christina Mattina
In 2022, the articles published in the peer-reviewed The American Journal of Managed Care® (AJMC®) explored care management interventions, savings from biosimilars, and much more.
Biosimilars Are a "Wonderful" Option for Patients With Cancer, Says Susan Sabo-Wagner
December 23rd 2022

Biosimilars Are a "Wonderful" Option for Patients With Cancer, Says Susan Sabo-Wagner

Justina Petrullo Allison Inserro
Biosimilars are a wonderful option for patients, but the growing number available can be challenging to manage when different payers prefer different agents, said Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy for Oncology Consultants of Houston, Texas.
Top 5 Most Popular Biosimilars Content of 2022
December 20th 2022

Top 5 Most Popular Biosimilars Content of 2022

Laura Joszt, MA
The top biosimilars content of 2022 reviewed perceptions around switching to a trastuzumab biosimilar, drug costs, and the successful implementation of biosimilars in practice.
rendering of a molecule
December 14th 2022

Tocilizumab Biosimilars Show Similar Safety, Tolerability, Immunogenicity to Reference: ACR Abstracts

Laura Joszt, MA
Abstracts presented at the annual meeting of the American College of Rheumatology (ACR) show 2 tocilizumab biosimilars were comparable to the reference product.
AJAC
December 8th 2022

Oncologists’ Perceptions and Utilization of US Therapeutic Oncology Biosimilars

Sonia Tadjalli Oskouei, PharmD, BCMAS Stephanie Fortier, PhD Yolaine Jeune-Smith, PhD Ajeet Gajra, MD
Biosimilar use in clinical practice is determined by oncologists’ perceptions of and willingness to prescribe them. The authors investigated US oncologists’ perceptions and use of biosimilars.
health care cost image of stethoscope lying on top of $100 bills
December 5th 2022

US Biosimilars Substantially More Expensive Than Those in Germany, Switzerland

Laura Joszt, MA
Due to anticompetitive practices, the United States lags Germany and Switzerland in the number of biosimilars on the market, while also having substantially higher prices for both biosimilars and reference products.
row of identical vials
November 26th 2022

Driving Biosimilar Uptake in Rheumatology, Biosimilar-to-Biosimilar Switching: ACR Abstracts

Laura Joszt, MA
Abstracts show that institutions can make internal changes to drive the use of biosimilars and that successful biosimilar-to-biosimilar switching is based on patient-related factors.
Congress
November 23rd 2022

Senate Bill Would Forbid Switching Studies to Gain Interchangeability Status

Laura Joszt, MA
A bill introduced by Senator Mike Lee, R-Utah, would prohibit the FDA requiring switching studies for biosimilars to gain interchangeability status.
molecule
November 16th 2022

RWE Shows Biosimilar Switching Safe and Effective to Treat Psoriasis

Laura Joszt, MA
Switching from the originator products to biosimilars or between biosimilars is safe and effective, according to a review of real-world studies.
Timothy Murphy, MD, Rocky Mountain Cancer Centers
November 13th 2022

Dr Timothy Murphy: Strong Communication Is Necessary for Practices Stocking Multiple Biosimilars

Laura Joszt, MA
With multiple biosimilars approved for a reference product and different payers preferring particular products, communication between the clinical pharmacy team and the managed care team is crucial, said Timothy Murphy, MD, FACP, medical oncologist/hematologist with Rocky Mountain Cancer Centers.
Site Logo
November 9th 2022

The Price Paradox of Biosimilar-Like Long-Acting Insulin

Morgane C. Mouslim, DVM, ScM Emaan S. Rashidi, MHS Joseph F. Levy, PhD Mariana P. Socal, MD, PhD Antonio J. Trujillo, PhD
Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.
rows of identical vials
November 4th 2022

Rheumatologists Grow More Comfortable With Biosimilars, but Concerns Remain

Laura Joszt, MA
Ahead of the big wave of adalimumab biosimilars launching in the US market in 2023, rheumatologists report growing confidence in using biosimilars but remain concerned about their efficacy and economic benefit.
Timothy Murphy, MD, Rocky Mountain Cancer Centers
October 28th 2022

Dr Timothy Murphy Discusses Successfully Implementing Biosimilars Into Community Cancer Practice

Laura Joszt, MA
Having a plan in place to educate providers and the pharmacy team has contributed to the success that Rocky Mountain Cancer Centers (RMCC) has had with rapidly implementing biosimilars, said Timothy Murphy, MD, medical oncologist/hematologist with RMCC.
Multidisciplinary Care as the Catalyst for Innovation in Oncology
October 21st 2022

Multidisciplinary Care as the Catalyst for Innovation in Oncology

Matthew Gavidia
Coverage from the Atlanta meeting of the Institute for Value-Based Medicine, chaired by Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services, Emory Healthcare and Emory Winship Cancer Institute.
Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology
October 16th 2022

Dr Paul Forsberg Highlights the Role of the Reference Product Once Biosimilars Hit the Market

Laura Joszt, MA
Biosimilars have had such an impact on driving down costs, that in some instances the reference product might be the lowest cost option, explained Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
Congress
October 12th 2022

House Bill Takes Aim at Barriers to Biosimilar Substitution

AJMC Staff
The bill was introduced by 2 Republicans and 2 Democrats and would direct HHS to undertake a study to understand how substitution of interchangeable biologic products may be impeded.
Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology
October 9th 2022

Considering When to Switch Patients From One Biosimilar to Another

Laura Joszt, MA
With more and more biosimilars reaching market, there are considerations around whether to keep patients on their current biosimilar or switch them to another biosimilar as the market dictates, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
<123456789
...
20>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo